دورية أكاديمية
أعرض في EDS

Neutralizing antibody responses to SARS-CoV-2 Omicron variants: Post six months following two-dose & three-dose vaccination of ChAdOx1 nCoV-19 or BBV152.

التفاصيل البيبلوغرافية
العنوان: Neutralizing antibody responses to SARS-CoV-2 Omicron variants: Post six months following two-dose & three-dose vaccination of ChAdOx1 nCoV-19 or BBV152.
المؤلفون: Yadav PD; Maximum Containment Laboratory, Pune, Maharashtra, India., Sardana V; Big Data and Informatics Unit, CSIR-Institute of Genomics & Integrative Biology, New Delhi, India.; Academy of Scientific & Innovative Research, Ghaziabad, Uttar Pradesh, India., Deshpande GR; Diagnostic Virology Group, Pune, Maharashtra, India., Shinde PV; Diagnostic Virology Group, Pune, Maharashtra, India., Thangaraj JWV; Department of Epidemiology & Biostatistics, ICMR-National Institute of Epidemiology, Chennai, Tamil Nadu, India., George LS; Division of Communicable Diseases, Indian Council of Medical Research, New Delhi, India., Sapkal GN; ICMR-National Institute of Virology, Pune, Maharashtra, India., Patil DY; Maximum Containment Laboratory, Pune, Maharashtra, India., Sahay RR; Maximum Containment Laboratory, Pune, Maharashtra, India., Shete AM; Maximum Containment Laboratory, Pune, Maharashtra, India., Joshi M; Department of Science & Technology, Gujarat Biotechnology Research Centre, Gandhinagar, Gujarat, India., Murhekar M; Department of Epidemiology & Biostatistics, ICMR-National Institute of Epidemiology, Chennai, Tamil Nadu, India., Godbole S; ICMR-National Institute of Virology, Pune, Maharashtra, India., Gupta N; Division of Communicable Diseases, Indian Council of Medical Research, New Delhi, India., Prakash S; Big Data and Informatics Unit, CSIR-Institute of Genomics & Integrative Biology, New Delhi, India.; Academy of Scientific & Innovative Research, Ghaziabad, Uttar Pradesh, India., Rathore M; Cardiometabolic Disease Unit, CSIR-Institute of Genomics & Integrative Biology, New Delhi, India.; Academy of Scientific & Innovative Research, Ghaziabad, Uttar Pradesh, India., Ujjainiya R; Cardiometabolic Disease Unit, CSIR-Institute of Genomics & Integrative Biology, New Delhi, India.; Academy of Scientific & Innovative Research, Ghaziabad, Uttar Pradesh, India., Singh AP; Cardiometabolic Disease Unit, CSIR-Institute of Genomics & Integrative Biology, New Delhi, India.; Academy of Scientific & Innovative Research, Ghaziabad, Uttar Pradesh, India., Mishra A; Cardiometabolic Disease Unit, CSIR-Institute of Genomics & Integrative Biology, New Delhi, India.; Academy of Scientific & Innovative Research, Ghaziabad, Uttar Pradesh, India., Dash D; Cardiometabolic Disease Unit, CSIR-Institute of Genomics & Integrative Biology, New Delhi, India.; Academy of Scientific & Innovative Research, Ghaziabad, Uttar Pradesh, India., Chaudhary K; Big Data and Informatics Unit, CSIR-Institute of Genomics & Integrative Biology, New Delhi, India.; Academy of Scientific & Innovative Research, Ghaziabad, Uttar Pradesh, India., Sengupta S; Big Data and Informatics Unit, CSIR-Institute of Genomics & Integrative Biology, New Delhi, India.; Academy of Scientific & Innovative Research, Ghaziabad, Uttar Pradesh, India.
مؤلفون مشاركون: ICMR Booster Dose Study Group
المصدر: The Indian journal of medical research [Indian J Med Res] 2024 Feb 01; Vol. 159 (2), pp. 223-231. Date of Electronic Publication: 2024 Apr 04.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Medknow Country of Publication: India NLM ID: 0374701 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 0971-5916 (Print) Linking ISSN: 09715916 NLM ISO Abbreviation: Indian J Med Res Subsets: MEDLINE
أسماء مطبوعة: Publication: <2011- > : Mumbai : Medknow
Original Publication: New Delhi : Council Of Medical Research
مواضيع طبية MeSH: ChAdOx1 nCoV-19* , COVID-19*/prevention & control , COVID-19 Vaccines* , Vaccines, Inactivated*, Humans ; SARS-CoV-2 ; Antibodies, Neutralizing ; Vaccination ; Antibodies, Viral
مستخلص: Background Objectives: The Omicron sub-lineages are known to have higher infectivity, immune escape and lower virulence. During December 2022 - January 2023 and March - April 2023, India witnessed increased SARS-CoV-2 infections, mostly due to newer Omicron sub-lineages. With this unprecedented rise in cases, we assessed the neutralization potential of individuals vaccinated with ChAdOx1 nCoV (Covishield) and BBV152 (Covaxin) against emerging Omicron sub-lineages.
Methods: Neutralizing antibody responses were measured in the sera collected from individuals six months post-two doses (n=88) of Covishield (n=44) or Covaxin (n=44) and post-three doses (n=102) of Covishield (n=46) or Covaxin (n=56) booster dose against prototype B.1 strain, lineages of Omicron; XBB.1, BQ.1, BA.5.2 and BF.7.
Results: The sera of individuals collected six months after the two-dose and the three-dose demonstrated neutralizing activity against all variants. The neutralizing antibody (NAbs) level was highest against the prototype B.1 strain, followed by BA5.2 (5-6 fold lower), BF.7 (11-12 fold lower), BQ.1 (12 fold lower) and XBB.1 (18-22 fold lower).
Interpretation Conclusions: Persistence of NAb responses was comparable in individuals with two- and three-dose groups post six months of vaccination. Among the Omicron sub-variants, XBB.1 showed marked neutralization escape, thus pointing towards an eventual immune escape, which may cause more infections. Further, the correlation of study data with complete clinical profile of the participants along with observations for cell-mediated immunity may provide a clear picture for the sustained protection due to three-dose vaccination as well as hybrid immunity against the newer variants.
(Copyright © 2024 Copyright: © 2024 Indian Journal of Medical Research.)
References: Nat Commun. 2022 May 5;13(1):2476. (PMID: 35513437)
J Travel Med. 2021 Oct 11;28(7):. (PMID: 34343316)
J Travel Med. 2022 May 31;29(3):. (PMID: 35244698)
Nat Med. 2022 Mar;28(3):496-503. (PMID: 35090165)
Vaccine. 2023 Mar 24;41(13):2234-2242. (PMID: 36858871)
Elife. 2021 Apr 20;10:. (PMID: 33876727)
Lancet Infect Dis. 2023 Jan;23(1):28-30. (PMID: 36543471)
Lancet Reg Health Eur. 2021 Nov;10:100208. (PMID: 34514454)
Lancet. 2021 Dec 11;398(10317):2126-2128. (PMID: 34871545)
Front Immunol. 2023 May 17;14:1166261. (PMID: 37266444)
Indian J Med Res. 2020 Jul & Aug;152(1 & 2):82-87. (PMID: 32859866)
Sci Rep. 2022 Jul 14;12(1):12038. (PMID: 35835822)
Lancet Infect Dis. 2023 May;23(5):556-567. (PMID: 36681084)
BMJ. 2023 Jan 19;380:153. (PMID: 36657748)
Nat Commun. 2022 Apr 1;13(1):1726. (PMID: 35365648)
JAMA. 2023 Feb 21;329(7):531. (PMID: 36723971)
Lancet. 2022 Feb 12;399(10325):625-626. (PMID: 35063123)
Front Microbiol. 2022 Aug 09;13:942659. (PMID: 36016787)
J Travel Med. 2022 Sep 17;29(6):. (PMID: 35900009)
Cell Discov. 2023 Jun 27;9(1):64. (PMID: 37369648)
Nat Med. 2023 Feb;29(2):344-347. (PMID: 36473500)
JAMA Netw Open. 2022 Sep 1;5(9):e2231778. (PMID: 36107426)
J Infect. 2022 Jun;84(6):834-872. (PMID: 35318093)
Cell Host Microbe. 2022 Nov 9;30(11):1518-1526.e4. (PMID: 36240764)
Cell Rep. 2023 May 30;42(5):112443. (PMID: 37104089)
Clin Infect Dis. 2022 Dec 19;75(12):2243-2246. (PMID: 35686300)
Front Immunol. 2022 Apr 29;13:876037. (PMID: 35572536)
Lung India. 2022 Nov-Dec;39(6):525-531. (PMID: 36629231)
Viruses. 2022 Feb 24;14(3):. (PMID: 35336868)
J Infect. 2022 May;84(5):e80-e81. (PMID: 35157945)
Science. 2021 Nov 19;374(6570):995-999. (PMID: 34648303)
Med. 2022 Apr 8;3(4):262-268.e4. (PMID: 35313451)
J Travel Med. 2021 Jun 1;28(4):. (PMID: 33772577)
Sci Transl Med. 2022 Mar 23;14(637):eabn8057. (PMID: 35166573)
المشرفين على المادة: B5S3K2V0G8 (ChAdOx1 nCoV-19)
76JZE5DSN6 (BBV152 COVID-19 vaccine)
0 (Antibodies, Neutralizing)
0 (Antibodies, Viral)
0 (COVID-19 Vaccines)
0 (Vaccines, Inactivated)
SCR Organism: SARS-CoV-2 variants
تواريخ الأحداث: Date Created: 20240322 Date Completed: 20240408 Latest Revision: 20240428
رمز التحديث: 20240428
مُعرف محوري في PubMed: PMC11050759
DOI: 10.4103/ijmr.ijmr_948_23
PMID: 38517215
قاعدة البيانات: MEDLINE
الوصف
تدمد:0971-5916
DOI:10.4103/ijmr.ijmr_948_23